Powering therapeutic possibility
Continuity Biosciences was founded on a simple belief: therapeutic potential can be amplified through precision delivery.
Our approach
Too often, promising therapies are limited not by what they are designed to do, but by the challenge of getting them to the right place. Treatments may disperse too broadly, struggle to penetrate the intended tissue, or fail to remain where they are needed long enough to deliver their full effect.
We are working to change that.
Our platforms are designed to help therapies reach target tissues with greater precision and purpose. Across small molecules, biologics, and cell-based therapies, we believe better delivery can expand what medicine is able to achieve.
Marco Farina, PhD, NICHE project lead
Breakthrough technologies don't build themselves.
They require people willing to operate at the edge of what's known and to do the hard work of turning new ideas into something clinically meaningful.
Continuity Biosciences was founded by Alessandro Grattoni, Ramakrishna Venugopalan, and Robert Whitehead, a team that unites deep expertise across therapeutic delivery, medicine, and product strategy. Our science is rooted in research from Houston Methodist, and our advisory network brings experience across research, care delivery, regulation, and commercialization—giving us the rare ability to move fluidly from bench to bedside.
What drives us is not just scientific rigor, but imagination, persistence, and a genuine belief that delivery is where therapeutic potential can be won or lost. Our collective work spans 135 publications and 80 patents, not as a measure of the past, but as a foundation for what comes next.
How we turn precision into possibility
We are driven by the opportunity to expand what new and existing therapies can achieve in improving patient outcomes. This vision continues to shape everything we do.
This is why we are developing adaptive, therapy-agnostic delivery platforms designed to improve how therapeutic treatments reach and act at their intended sites of action. Rather than building around a single therapy or disease, we are building technologies that can support a wide range of applications where delivery is central to performance.
Delivery platforms, built to flex.
Advancing the
next chapter of therapeutic delivery
We believe better delivery can help shape what comes next in medicine.
As we continue to advance our platforms, we welcome conversation with partners and collaborators who share our excitement about what becomes possible when therapies can reach where they are needed most.
NDES and NanoDDI Project Lead